Use of targeted cationic liposomes in enhanced DNA delivery to cancer cells.

abstract：:The herpes simplex virus thymidine kinase gene (HSV-TK) in combination with ganciclovir (GCV), is currently being used in gene therapy-based clinical trials for cancer treatment. Its therapeutic effect is based on a "bystander effect" whereby HSV-TK gene-modified tumor cells are toxic to nearby unmodified tumor cells ...

journal_title：Cancer gene therapy

authors： Ramesh R,Munshi A,Abboud CN,Marrogi AJ,Freeman SM

更新日期：1996-11-01 00:00:00

abstract：:Apoptotic pathways are initiated as a cellular defense mechanism to eliminate adenovirus-infected cells. We have investigated how E1A-induced apoptosis interferes with viral replication in cancer cells. We found that E1B19K alone can efficiently suppress E1A-induced apoptosis in cancer cells. Viruses deleted for both ...

journal_title：Cancer gene therapy

authors： Rao XM,Tseng MT,Zheng X,Dong Y,Jamshidi-Parsian A,Thompson TC,Brenner MK,McMasters KM,Zhou HS

更新日期：2004-09-01 00:00:00

abstract：:Oncolytic herpes simplex virus (HSV) vectors have been used in early phase human clinical trials as a therapy for recurrent malignant glioblastoma. This treatment proved safe but limited improvements in patient survival were observed. The potency of these vectors might be enhanced by targeting vector infectivity to tu...

journal_title：Cancer gene therapy

authors： Grandi P,Fernandez J,Szentirmai O,Carter R,Gianni D,Sena-Esteves M,Breakefield XO

更新日期：2010-09-01 00:00:00

abstract：:Multiple myeloma (MM) accounts for 10% of hematological malignant disorders. Its refractory nature indicates the necessity of developing novel therapeutic modalities. Since interleukin 6 (IL-6) is one of the major growth factors for MM cells, we expressed suppressor of cytokine signaling-1 (SOCS-1), one of the blockad...

journal_title：Cancer gene therapy

authors： Yamamoto M,Nishimoto N,Davydova J,Kishimoto T,Curiel DT

更新日期：2006-02-01 00:00:00

abstract：:The majority of human neuroblastomas express low to undetectable levels of major histocompatibility complex (MHC) class I and II antigens (MHC-I and -II). We studied the effects of gamma interferon (gamma-IFN) transduction on expression of these antigens in six human neuroblastoma cell lines with and without genomic a...

journal_title：Cancer gene therapy

authors： Uçar K,Seeger RC,Challita PM,Watanabe CT,Yen TL,Morgan JP,Amado R,Chou E,McCallister T,Barber JR

更新日期：1995-09-01 00:00:00

abstract：:The human papillomaviruses (HPVs) are a diverse group of infectious agents, some of which are a causative agent of human cancers. Cervical cancer and oral cancer are closely associated with specific types of HPV, and the tumors grow only if there is continual expression of the viral E6 and E7 genes. Evidence from in v...

journal_title：Cancer gene therapy

authors： Shillitoe EJ

更新日期：2006-05-01 00:00:00

abstract：:We recently described a novel nonviral/viral vector for gene transfer, the plasmovirus (Noguiez-Hellin P, Robert-le Meur M, Laune S, et al. C R Acad Sci Paris, Sciences de la Vie. 1996;319:45-50; Noguiez-Hellin P, Robert-le Meur M, Salzmann J-L, et al. Proc Natl Acad Sci USA. 1996;93:4175-4180). Plasmoviruses are plas...

journal_title：Cancer gene therapy

authors： Morozov VA,Noguiez-Hellin P,Laune S,Tamboise E,Salzmann JL,Klatzmann D

更新日期：1997-09-01 00:00:00

abstract：:Apatinib, a selective vascular endothelial growth factor receptor 2-tyrosine kinase inhibitor, has demonstrated activity against a wide range of solid tumors, including advanced hepatocellular carcinoma (HCC). Preclinical and preliminary clinical results have confirmed the synergistic antitumor effects of apatinib in ...

journal_title：Cancer gene therapy

authors： Yang Y,Wang C,Sun H,Jiang Z,Zhang Y,Pan Z

更新日期：2020-06-12 00:00:00

abstract：:The use of prodrug-activated ("suicide") gene therapy has been shown to be effective in inducing tumor regression when only a small proportion of tumor cells contains the suicide gene. These experiments were designed to test whether additional therapeutic benefit may be obtained by stimulating the immune response. Mur...

journal_title：Cancer gene therapy

authors： Jones RK,Pope IM,Kinsella AR,Watson AJ,Christmas SE

更新日期：2000-12-01 00:00:00

abstract：:Despite the fact that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can selectively induce apoptosis in cancer cells, TRAIL resistance in cancer cells has challenged the use of TRAIL as a therapeutic agent. First, prostate carcinoma cell lines (DU145, LNCaP and PC3) were screened for sensitivity to a...

journal_title：Cancer gene therapy

authors： Sanlioglu AD,Koksal IT,Karacay B,Baykara M,Luleci G,Sanlioglu S

更新日期：2006-01-01 00:00:00

abstract：:A phase I clinical trial using autologous, IL-7 gene-modified tumor cells in patients with disseminated melanoma has been recently completed. Although no major clinical responses were observed, increased antitumor cytotoxicity was measured in postvaccine peripheral blood lymphocytes in a subset of treated patients. To...

journal_title：Cancer gene therapy

authors： Carsana M,Tragni G,Nicolini G,Bersani I,Parmiani G,Anichini A,Sun YS,Möller P,Schadendorf D,Sensi ML

更新日期：2002-03-01 00:00:00

abstract：:The purpose of this study was to determine the feasibility of cytokine gene delivery to lymphatic tissue using transduced bone marrow-derived cells. MBAE and pBABE retroviral vectors carrying the genes for murine interleukin-4 and the selection marker neomycin phosphotransferase (neo) were used to transduce bone marro...

journal_title：Cancer gene therapy

authors： Fiehn C,Wettschureck N,Krauthoff A,Haas R,Ho AD

更新日期：2000-08-01 00:00:00

abstract：:Nuclear factor-kappa B (NF-κB) has a pivotal role in the progression and distant metastasis of cancers, including malignant bone tumors. To inhibit NF-κB activation, a new molecular therapy using synthetic double-stranded oligodeoxynucleotide (ODN) as a 'decoy' cis element against NF-κB has been developed. To determin...

journal_title：Cancer gene therapy

authors： Nishimura A,Akeda K,Matsubara T,Kusuzaki K,Matsumine A,Masuda K,Gemba T,Uchida A,Sudo A

更新日期：2011-04-01 00:00:00

abstract：:Adenovirus (Adv)-mediated herpes simplex virus thymidine kinase (adv/tk) gene therapy combined with ganciclovir (GCV) medication is a promising approach for the treatment of malignant glioma. However, optimal administration and the effect of possible adjuvant treatments have not been fully examined. In the present stu...

journal_title：Cancer gene therapy

authors： Tyynelä K,Sandmair AM,Turunen M,Vanninen R,Vainio P,Kauppinen R,Johansson R,Vapalahti M,Ylä-Herttuala S

更新日期：2002-11-01 00:00:00

abstract：:It has been demonstrated that survivin, a novel member of the inhibitor of apoptosis (IAP) protein family, is expressed in human cancers but is undetectable in normal differentiated tissues. We employed a recombinant adenoviral vector (reAdGL3BSurvivin) in which a tumor-specific survivin promoter and a luciferase repo...

journal_title：Cancer gene therapy

authors： Zhu ZB,Makhija SK,Lu B,Wang M,Kaliberova L,Liu B,Rivera AA,Nettelbeck DM,Mahasreshti PJ,Leath CA,Barker S,Yamaoto M,Li F,Alvarez RD,Curiel DT

更新日期：2004-04-01 00:00:00

abstract：:Typically, gene transfer strategies utilize a promoter/transgene arrangement that treat these elements independently and do not offer any interplay between them. Our goal was to establish a promoter/transgene combination that would result in improvement in both expression and therapeutic effect by utilizing the transc...

journal_title：Cancer gene therapy

authors： Strauss BE,Bajgelman MC,Costanzi-Strauss E

更新日期：2005-12-01 00:00:00

abstract：:We present here the updated results after 9 years of the beginning of a trial on canine patients with malignant melanoma. This surgery adjuvant approach combined local suicide gene therapy with a subcutaneous vaccine composed by tumor cells extracts and xenogeneic cells producing human interleukin-2 and granulocyte-ma...

journal_title：Cancer gene therapy

authors： Finocchiaro LM,Glikin GC

更新日期：2012-12-01 00:00:00

abstract：:The growth of new blood vessels is an essential condition for the development of tumors with a diameter greater than 1-2 mm and also for their metastatic dissemination. RNasin, the placental ribonuclease inhibitor, is known to have antiangiogenic activity through the inhibition of angiogenin and basic fibroblast growt...

journal_title：Cancer gene therapy

authors： Botella-Estrada R,Malet G,Revert F,Dasí F,Crespo A,Sanmartín O,Guillén C,Aliño SF

更新日期：2001-04-01 00:00:00

abstract：:We report that radiation enhances the antitumor efficacy of the oncolytic adenovirus vector VRX-007 in Syrian hamster tumors. We used tumor-specific irradiation of subcutaneous tumors and compared treatment options of radiation alone or combined with VRX-007 and cyclophosphamide (CP). Radiation therapy further augment...

journal_title：Cancer gene therapy

authors： Young BA,Spencer JF,Ying B,Toth K,Wold WS

更新日期：2013-09-01 00:00:00

abstract：:RNA interference is an endogenous gene-silencing mechanism that involves double-stranded RNA-mediated sequence-specific mRNA degradation. The discovery of this pathway together with the elucidation of the structure and function of short interfering RNAs--the effector molecules of RNA interference--has had an enormous ...

journal_title：Cancer gene therapy

authors： Karagiannis TC,El-Osta A

更新日期：2005-10-01 00:00:00

abstract：:As of January 2005, there were 1020 gene therapy clinical trials ongoing worldwide with 675 or 66.2% devoted to cancer gene therapy. The majority are occurring in the US and Europe (http://www.wiley.co.uk/genetherapy/clinical/). At the present time, to our knowledge there are no trials that employ gene delivery of Fas...

journal_title：Cancer gene therapy

authors： Norris JS,Bielawska A,Day T,El-Zawahri A,ElOjeimy S,Hannun Y,Holman D,Hyer M,Landon C,Lowe S,Dong JY,McKillop J,Norris K,Obeid L,Rubinchik S,Tavassoli M,Tomlinson S,Voelkel-Johnson C,Liu X

更新日期：2006-12-01 00:00:00

abstract：:At the Eleventh International Conference on Gene Therapy of Cancer (December 12-14, 2002, San Diego, CA) progress on using gene transfer technology to treat cancer was presented. Although there is as yet no cancer gene therapy being marketed, considerable progress has been made in defining likely strategies and likely...

journal_title：Cancer gene therapy

authors： Gottesman MM

更新日期：2003-07-01 00:00:00

abstract：:In this study, we have applied high-density oligonucleotide microarray technology to characterize biologic changes associated with adenoviral vector-mediated target cell infection. We infected a human melanoma cell line, M21, with the tropism-modified vectors, Ad5lucRGD and Ad5/3luc1. In addition, we infected the M21 ...

journal_title：Cancer gene therapy

authors： Volk AL,Rivera AA,Page GP,Salazar-Gonzalez JF,Nettelbeck DM,Matthews QL,Curiel DT

更新日期：2005-02-01 00:00:00

abstract：:Recurrent fusion genes (FGs) with clinical significances in leukemias are mainly mutually exclusive, and the coexistence of different FGs has been rarely reported. In this study, we retrospectively analyzed the incidence, genetic characteristics, and prognosis of leukemias with concurrent pathogenic FGs, which commonl...

journal_title：Cancer gene therapy

authors： Chen X,Wang F,Wang T,Zhang Y,Ma X,Yuan L,Teng W,Guo L,Liu M,Liu M,Chen J,Nie D,Zhang Y,Zhou X,Wang M,Chen KN,Zhu P,Liu H

更新日期：2020-02-01 00:00:00

abstract：:Mesenchymal stem cells (MSCs) have affinity to tumor sites where they home, affecting their biology and growth. Previously, we have isolated mesenchymal cells from the decidua of the human placenta named as decidua-derived MSCs (DMSCs). The aims of the present study were to investigate the migration capacity of DMSCs ...

journal_title：Cancer gene therapy

authors： Vegh I,Grau M,Gracia M,Grande J,de la Torre P,Flores AI

更新日期：2013-01-01 00:00:00

abstract：:Most cancer vaccines to date have made use of common tumor antigens or allogenic cancer cell lines. The majority of tumor antigens may, however, be unique patient-specific antigens. Dendritic cells (DCs) are the most potent antigen-presenting cells known. The present report is a full-scale preclinical evaluation of au...

journal_title：Cancer gene therapy

authors： Kyte JA,Kvalheim G,Aamdal S,Saebøe-Larssen S,Gaudernack G

更新日期：2005-06-01 00:00:00

abstract：:Endothelial cells and endothelial cell precursors encoding a therapeutic gene have induced antitumor responses in preclinical models. Culture of peripheral blood provides a rich supply of autologous, highly proliferative endothelial cells, also referred to as blood outgrowth endothelial cells (BOECs). The aim of this ...

journal_title：Cancer gene therapy

authors： Bodempudi V,Ohlfest JR,Terai K,Zamora EA,Vogel RI,Gupta K,Hebbel RP,Dudek AZ

更新日期：2010-12-01 00:00:00

abstract：:To identify the differentially expressed genes (DEGs) and their transcription factors (TFs) in colorectal cancer (CRC). We performed an integrated analysis of microarray studies. Functional annotation and CRC-specific transcriptional regulatory network construction were performed. Expression of selected DEGs and TFs w...

journal_title：Cancer gene therapy

authors： Liu HY,Zhang CJ

更新日期：2017-06-01 00:00:00

abstract：:There is growing evidence that combinations of antiangiogenic proteins with other antineoplastic treatments such as chemo- or radiotherapy and suicide genes-mediated tumor cytotoxicity lead to synergistic effects. In the present work, we tested the activity of two non-replicative herpes simplex virus (HSV)-1-based vec...

journal_title：Cancer gene therapy

authors： Berto E,Bozac A,Volpi I,Lanzoni I,Vasquez F,Melara N,Manservigi R,Marconi P

更新日期：2007-09-01 00:00:00

abstract：:Oncolytic viruses (OVs) have shown great anti-cancer potential in animal models, but only modest success in early clinical trials. A better understanding of the mechanisms underlining OV efficacy is needed to resolve this discrepancy. In the clinic, OV therapy will likely be combined with traditional chemotherapy, und...

journal_title：Cancer gene therapy

authors： Granot T,Meruelo D

更新日期：2012-08-01 00:00:00